The HCFO program ended in December 2016.
This site will no longer be updated, and some elements may not appear correctly.
Study on Informed Choice of Drug Coverage for Medicare Beneficiaries
Grant Description: Is Medicare Part D drug benefit a cost-effective option for healthy Medicare beneficiaries? The researchers hypothesized that seniors use current expenditures to estimate their need for coverage, which could result in a significant underestimate of the true risk. The objective of the project was to evaluate the cost-effectiveness of Medicare Part D for healthy beneficiaries and provide accurate lifetime drug cost information to help seniors make more informed decisions regarding Medicare Part D coverage.
Policy Summary: Beginning in 2006, Medicare’s Part D benefit offered outpatient prescription drug coverage to beneficiaries. Medicare beneficiaries have a choice to enroll in Part D drug coverage as soon as they are eligible for Medicare, or to postpone enrollment in Part D until they contract a drug-intensive condition. Postponed enrollment saves the beneficiary the cost of premiums, but adds the cost of a late enrollment penalty if the beneficiary decides to enroll in Part D at a later date. Immediate enrollment clearly is of interest of beneficiaries who have a drug-intensive condition because premiums are not risk-rated and are subsidized heavily by the government. The enrollment decision for a healthy beneficiary is less clear. In order to make an informed enrollment decision, healthy Medicare beneficiaries must have estimates of (a) the lifetime probability that they will contract a drug-intensive condition; (b) their length of survival with the condition; (c) their expected annual drug expenditures with the condition, with and without coverage; and (d) the amount of the late enrollment penalty. Prior to this study the first three estimates were not readily available to beneficiaries. Lifetime probabilities of contracting drug-intensive conditions were available for only a few conditions. Using MCBS data from the period 1993 to 2002, the researchers combined estimates of these cost components to obtain estimated lifetime out-of-pocket expenditures on outpatient prescription drugs, premiums and late enrollment penalties for healthy 65-year-old Medicare beneficiaries if they purchase Part D as soon as they are eligible versus waiting until they contract a drug-intensive condition. The researchers found that the late enrollment penalty provides an important incentive for early enrollment. Eliminating the late enrollment penalty would create a significant cost advantage for postponed enrollment, particularly for men. We also found that the advantage of coverage for healthy beneficiaries – lower out-of-pocket costs – is offset to a degree by the increased spending that results from having prescription drug coverage (moral hazard). Our analysis provides information on only one input to beneficiaries’ Part D enrollment decisions – out-of-pocket spending. Other important factors include the beneficiary’s aversion to risk and the value they place on the additional expenditure on drug consumption induced by Part D coverage, but these factors also favor immediate purchase. The researchers’ estimates and microsimulation model provide a flexible analytic platform that could be used to simulate a variety of policy options regarding the structure of the Part D benefit.
Search Grants & Grantees